Alvotech and advanz pharma enter into european supply and commercialization agreement for biosimilar candidate to cimzia® (certolizumab pegol)

Reykjavik,  iceland and london, uk (july 1, 2025) — alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and advanz pharma holdco limited (“advanz pharma”), a uk headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in europe, today announced that the companies have entered into a supply and commercialization agreement for avt10, alvotech's biosimilar candidate to cimzia® (certolizumab pegol).
ALVO Ratings Summary
ALVO Quant Ranking